RQ-00203066

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRQ-00203066
Drug Alias Namesodium channel blockers - RaQualia Pharma
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type III alpha subunit blockers
TargetsSodium channel protein type III alpha subunit
Therapy Area/IndicationsPainNeuralgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRaqualia Pharma IncPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRaqualia Pharma IncPfizer Inc
Active IndicationsN/A
Inactive IndicationsPainNeuralgia

Other Information

ATC CodeN/A
Related LinksN/A